View PDF Version - RePub - Erasmus Universiteit Rotterdam

COnTEnTS
Chapter 1 General Introduction 7
1.1. Immune therapy for the treatment of tumors 9
1.2. Challenges of TCR gene therapy 14
1.3 Mouse tumor models for TCR gene therapy 14
1.3.1 Genetically engineered mouse tumor models 16
1.3.2 Environmentally induced tumor models 19
1.3.3 Transplantable tumor models 19
1.4. Target antigens and TCR transgenes: topics of this thesis 21
1.4.1 Safe target antigens 21
1.4.2 T cell receptors 23
1.5 Aims and scope of this thesis 25
Chapter 2 TCR gene therapy to treat melanoma: lessons from clinical and preclinical
studies.
Expert Opinion Biological Therapies 2010; 10(4):547-62
Chapter 3 T cell receptor gene therapy in human melanoma-bearing immunedeficient
mice: human but not mouse T cells recapitulate outcome of
clinical studies
Human Gene Therapy 2011; 23(2):187-201
Chapter 4 Tumor relapse following T cell receptor gene therapy is not due to loss of
immunogenicity
Manuscript submitted
Chapter 5 TCR gene transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 epitopes as
Melanoma-Specific Immune targets
Clinical and Developmental Immunology 2012 (2012); ID 586314
Chapter 6 General discussion 161
6.1 Immune deficient mouse models for TCR gene therapy 162
6.1.2 Human TCR T cells in immune-deficient mice 162
6.1.3 Mouse TCR T cells in immune-deficient mice 164
6.2 Immune-competent mouse melanoma model for TCR gene therapy 165
6.2.1 Major findings of the HLA-A2tg melanoma mouse model 166
6.2.2 Characteristics of the HLA-A2tg melanoma mouse model 166
41
73
103
135